The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Open accessPublished version of a preprint
Abstract
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease 3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies 6-8 and dismal outcomes 9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations 10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment outcomes for patients with TP53 mutations are poor with available therapies.8-12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The TP53 mutation burden (ie, high variant allele frequency [VAF], concurrent complex karyotype, and/or multihit state) is integrally linked to inferior survival with median OS of 6-8 months.8-10,12”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, remissions in TP53-mutant patients are brief with a median overall survival (OS) ranging from 5 to 12 months,8,9,12,13,15-17”
From Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) represent a distinct molecular cohort with poor outcomes.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 gene mutations (mTP53) are found in up to 20% of myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) pts and 30%–40% of therapy‐related (TR) MDS/AML cases”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, mTP53 patients with a high variant allele frequency (VAF; i.e., >20%–23%), biallelic state, and/or complex karyotype (CK) have particularly poor risk.”
From Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Despite the known dominant negative and/or gain of function effect of certain TP53 mutations28,42, loss of the TP53-WT allele, a genetic event associated with a particularly dismal prognosis2, confers an additional fitness advantage to TP53-sAML LSCs.”
From Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution (2023) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Self-citation
Cited by
Sorted by citations
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Self-citationArber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citationMolecular International Prognostic Scoring System for Myelodysplastic Syndromes
Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200008 · Cited by 867
Self-citationCazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
Self-citationEprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
“PRD (63-97) DBD (102-292) TET (323-356) REG (363-393) TAD2 (43-62) TAD1 (1-42) CR mCR + HI mCR HI SD PD NR/NE”
Self-citationPrediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
Weeks, L. D., Niroula, A., Neuberg, D. S., Wong, W. J., Lindsley, R. C., Luskin, M. R., Berliner, N., Stone, R. M., DeAngelo, D. J., Soiffer, R. J., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200310 · Cited by 351
Self-citationEmerging agents and regimens for AML
Liu, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01062-w · Cited by 312
Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood · doi:10.1182/blood.2021014472 · Cited by 305
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q. C., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 309
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, E. J., Bagg, A., Hasserjian, R. P., Dinardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., et al. (2022) · Blood · doi:10.1182/blood.2022015853 · Cited by 235
Self-citationTP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg, O. K., Siddon, A. J., Madanat, Y. F., Gagan, J., Arber, D. A., Cin, P. D., Narayanan, D., Ouseph, M. M., Kurzer, J. H., & Hasserjian, R. P. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006239 · Cited by 203
Self-citationUnified classification and risk-stratification in Acute Myeloid Leukemia
Tazi, Y., Ossa, J. A., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S. D., Pradat, Y., Johnson, S. J., Hills, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32103-8 · Cited by 195
Self-citationKennedy, A. L., Myers, K. C., Bowman, J. R., Gibson, C. J., Camarda, N. D., Furutani, E., Muscato, G. M., Klein, R. H., Ballotti, K., Liu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21588-4 · Cited by 197
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
Makishima, H., Saiki, R., Nannya, Y., Korotev, S. C., Gurnari, C., Takeda, J., Momozawa, Y., Best, S., Krishnamurthy, P., Yoshizato, T., et al. (2022) · Blood · doi:10.1182/blood.2022018221 · Cited by 165
Self-citationOutcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161
Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01480-1 · Cited by 158
“If an exact match was not found, then for every tree node, the loss of assigning a cell to that node was calculated using the following loss function: l(M) = log (ADO) (M [1, 2] +M [3, 2]) + log (FD) (M [2, 1] +M [2, 3]) +log(ADO(2)FD)(M [1, 3] +M [3, 1]) where M is a confusion matrix generated across all loci of a ce…”
MethodDistinguishing AML from MDS: a fixed blast percentage may no longer be optimal
Estey, E. H., Hasserjian, R. P., & Döhner, H. (2021) · Blood · doi:10.1182/blood.2021011304 · Cited by 158
Self-citationShouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Afuye, A. O., Alperovich, A., Anagnostou, T., Besser, M. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02143 · Cited by 155
Self-citationLenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 156
Self-citationMascarenhas, J. O., Kosiorek, H. E., Prchal, J. T., Rambaldi, A., Berenzon, D., Yacoub, A., Harrison, C. N., McMullin, M. F., Vannucchi, A. M., Ewing, J., et al. (2022) · Blood · doi:10.1182/blood.2021012743 · Cited by 142
Self-citationCombined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01411-9 · Cited by 143
Self-citationEvolutionary trajectories of small cell lung cancer under therapy
George, J., Maas, L., Abedpour, N., Cartolano, M., Kaiser, L., Fischer, R. N., Scheel, A. H., Weber, J.-P., Hellmich, M., Bosco, G., et al. (2024) · Nature · doi:10.1038/s41586-024-07177-7 · Cited by 145
Sauta, E., Robin, M., Bersanelli, M., Travaglino, E., Meggendorfer, M., Zhao, L., Berrocal, J. C. C., Sala, C., Maggioni, G., Bernardi, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01784 · Cited by 123
Self-citationTashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013983 · Cited by 111
Current challenges and unmet medical needs in myelodysplastic syndromes
Platzbecker, U., Kubasch, A. S., Homer-Bouthiette, C., & Prébet, T. (2021) · Leukemia · doi:10.1038/s41375-021-01265-7 · Cited by 103
Self-citationYang, H., Garcia‐Manero, G., Sasaki, K., Bravo, G. M., Tang, Z., Wei, Y., Kadia, T. M., Chien, K. S., Rush, D. M., Ha, N. H., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01652-8 · Cited by 103
Contemporary Management of Acute Myeloid Leukemia
Venugopal, S., & Sekeres, M. A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2662 · Cited by 103
Diagnosis and classification of myelodysplastic syndromes
Hasserjian, R. P., Germing, U., & Malcovati, L. (2023) · Blood · doi:10.1182/blood.2023020078 · Cited by 99
Self-citationGuiding the global evolution of cytogenetic testing for hematologic malignancies
Akkari, Y. M. N., Baughn, L. B., Dubuc, A. M., Smith, A. C., Mallo, M., Cin, P. D., Díez‐Campelo, M., Gallego, M. S., Granada, I., Haase, D. T., et al. (2022) · Blood · doi:10.1182/blood.2021014309 · Cited by 92
Self-citationLi, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96
Garcia‐Manero, G., Goldberg, A. D., Winer, E. S., Altman, J. K., Fathi, A. T., Odenike, O. M., Roboz, G. J., Sweet, K. L., Miller, C., Wennborg, A., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00403-3 · Cited by 91
Molecular taxonomy of myelodysplastic syndromes and its clinical implications
Bernard, E., Hasserjian, R. P., Greenberg, P. L., Ossa, J. A., Creignou, M., Tuechler, H., Gutiérrez‐Abril, J., Domenico, D., Medina-Martinez, J. S., Levine, M. F., et al. (2024) · Blood · doi:10.1182/blood.2023023727 · Cited by 89
Self-citationThe genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms
Li, P., Brown, S., Williams, M., White, T., Xie, W., Cui, W., Peker, D., Lei, L., Kunder, C. A., Wang, H., et al. (2022) · Blood · doi:10.1182/blood.2021015135 · Cited by 87
Ochi, Y., Yoshida, K., Huang, Y., Kuo, M., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 85
Self-citationThe International Consensus Classification of acute myeloid leukemia
Weinberg, O. K., Porwit‐MacDonald, A., Orazi, A., Hasserjian, R. P., Foucar, K. K., Duncavage, E. J., & Arber, D. A. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03430-4 · Cited by 84
Self-citationPharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 97
What have we learned about TP53-mutated acute myeloid leukemia?
Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 88
Bauer, M., Jasinski‐Bergner, S., Mandelboim, O., Wickenhauser, C., & Seliger, B. (2021) · Cancers · doi:10.3390/cancers13205189 · Cited by 81
Versluis, J., Saber, W., Tsai, H. K., Gibson, C. J., Dillon, L. W., Mishra, A., McGuirk, J., Maziarz, R. T., Westervelt, P., Hegde, P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00866 · Cited by 78
Zeidner, J. F., Sallman, D. A., Récher, C., Daver, N. G., Leung, A. Y. H., Hiwase, D. K., Subklewe, M., Pabst, T., Montesinos, P., Larson, R. A., et al. (2025) · Blood · doi:10.1182/blood.2024027408 · Cited by 76
Optical genome mapping for structural variation analysis in hematologic malignancies
Smith, A. C., Neveling, K., & Kanagal‐Shamanna, R. (2022) · American Journal of Hematology · doi:10.1002/ajh.26587 · Cited by 69
Self-citationAnsari‐Pour, N., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Ajani, M., Reynier, J.-B., Tapinos, A., Pitt, J. J., Dentro, S. C., Woodard, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27079-w · Cited by 66
Loghavi, S., Kanagal‐Shamanna, R., Khoury, J. D., Medeiros, L. J., Naresh, K. N., Nejati, R., & Patnaik, M. M. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100397 · Cited by 69
Falini, B., & Martelli, M. P. (2023) · American Journal of Hematology · doi:10.1002/ajh.26812 · Cited by 62
Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes
Sirenko, M., Bernard, E., Creignou, M., Domenico, D., Farina, A., Ossa, J. A., Kosmider, O., Hasserjian, R. P., Jädersten, M., Germing, U., et al. (2024) · Blood · doi:10.1182/blood.2023023723 · Cited by 60
Self-citationIsabl Platform, a digital biobank for processing multimodal patient data
Medina-Martinez, J. S., Ossa, J. A., Levine, M. F., Zhou, Y., Gundem, G., Kung, A. L., & Papaemmanuil, E. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03879-7 · Cited by 59
Self-citationClonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia
Benard, B. A., Leak, L. B., Azizi, A., Thomas, D., Gentles, A. J., & Majeti, R. (2021) · Nature Communications · doi:10.1038/s41467-021-27472-5 · Cited by 62
Conventional chemotherapy: millions of cures, unresolved therapeutic index
Letai, A. G., & de Thé, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00778-4 · Cited by 58
Lane, A. A., Garcia, J. S., Raulston, E. G., Garzon, J. L., Galinsky, I. A., Baxter, E. W., Leonard, R., DeAngelo, D. J., Luskin, M. R., Reilly, C. R., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011721 · Cited by 57
Self-citationNovel precision medicine approaches and treatment strategies in hematological malignancies
Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P. H., Soulier, J., Hutchings, M., Östling, P., Cavelier, L. B., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13697 · Cited by 56
Self-citationClonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 63
Loke, J. C. T., Labopin, M., Craddock, C., Cornelissen, J. J., Labussière‐Wallet, H., Wagner-Drouet, E., van Gorkom, G. N. Y., Schaap, N. P., Kröger, N. M., Veelken, J. H., et al. (2022) · Cancer · doi:10.1002/cncr.34268 · Cited by 54
Stengel, A., Meggendorfer, M., Walter, W., Baer, C., Nadarajah, N., Hutter, S., Kern, W., Haferlach, T., & Haferlach, C. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010312 · Cited by 53
Bataller, Á., Garrido, A., Guijarro, F., Oñate, G., Díaz‐Beyá, M., Arnán, M., Tormo, M., Vives, S., Llano, M. P. Q. D., Coll, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005585 · Cited by 53
Tentori, C. A., Gregorio, C., Robin, M., Gagelmann, N., Gurnari, C., Ball, S., Berrocal, J. C. C., Lanino, L., D’Amico, S., Spreafico, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02175 · Cited by 53
Self-citationZhang, Y., Wu, J., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Wang, H., Zhang, P., Yan, X., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01718-7 · Cited by 54
Self-citationHow I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Chaer, F. E., Hourigan, C. S., & Zeidan, A. M. (2023) · Blood · doi:10.1182/blood.2022017808 · Cited by 51
Mechanisms adopted by cancer cells to escape apoptosis–A review
Dandoti, S. S. (2021) · Biocell · doi:10.32604/biocell.2021.013993 · Cited by 52
Guess, T. E., Potts, C. R., Bhat, P., Cartailler, J. A., Brooks, A., Holt, C., Yenamandra, A., Wheeler, F. C., Savona, M. R., Cartailler, J.-P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0128 · Cited by 50
Self-citationHow I diagnose and treat chronic myelomonocytic leukemia
Patnaik, M. M. (2022) · Haematologica · doi:10.3324/haematol.2021.279500 · Cited by 50
Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ładoń, D., Shultz, C. T., Al‐Kali, A., Brown, A. L., Chen, D., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00821-x · Cited by 50
Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 49
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
Bahaj, W., Kewan, T., Gurnari, C., Durmaz, A., Ponvilawan, B., Pandit, I., Kubota, Y., Ogbue, O. D., Zawit, M., Madanat, Y., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01480-y · Cited by 45
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
Newman, A. M., Zaka, M., Zhou, P., Blain, A. E., Erhorn, A., Barnard, A., Crossland, R. E., Wilkinson, S., Enshaei, A., Zordi, J. D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01444-6 · Cited by 46
Wu, J., Zhang, Y., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Jia, Y., Li, C., Wang, H., et al. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00328-4 · Cited by 46
Self-citationTP53 in MDS and AML: Biological and clinical advances
Zhao, Y., Chen, W., Yu, J., Pei, S., Zhang, Q., Shi, J., Huang, H., & Zhao, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216767 · Cited by 46
Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants
Inagaki‐Kawata, Y., Yoshida, K., Kawaguchi‐Sakita, N., Kawashima, M., Nishimura, T., Senda, N., Shiozawa, Y., Takeuchi, Y., Inoue, Y., Sato‐Otsubo, A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01301-9 · Cited by 44
Self-citationTP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates
Santini, V., Stahl, M. F., & Sallman, D. A. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432650 · Cited by 52
Self-citationBrieghel, C., Aarup, K., Torp, M. H., Andersen, M. A., Yde, C. W., Tian, X., Wiestner, A. U., Ahn, I. E., & Niemann, C. U. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4890 · Cited by 43
Developing a classification of hematologic neoplasms in the era of precision medicine
Cazzola, M., & Sehn, L. H. (2022) · Blood · doi:10.1182/blood.2022015849 · Cited by 43
Self-citationTP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
Hiwase, D., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al‐Kali, A., Sharplin, K. M., Ładoń, D., Hollins, R., Greipp, P. T., et al. (2022) · Blood · doi:10.1182/blood.2022018236 · Cited by 42
How I treat transplant-eligible patients with myelofibrosis
Kröger, N. M., Wolschke, C., & Gagelmann, N. (2023) · Blood · doi:10.1182/blood.2023021218 · Cited by 42
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, M. V., Arber, D. A., & Hiwase, D. (2025) · American Journal of Hematology · doi:10.1002/ajh.27655 · Cited by 43
The International Consensus Classification of myelodysplastic syndromes and related entities
Hasserjian, R. P., Orazi, A., Órfão, A., Rozman, M., & Wang, S. A. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03417-1 · Cited by 42
Self-citationBoscaro, E., Urbino, I., Catania, F. M., Arrigo, G., Secreto, C., Olivi, M., D’Ardìa, S., Frairia, C., Giai, V., Freilone, R., et al. (2023) · Cancers · doi:10.3390/cancers15133512 · Cited by 42
New Approaches to Myelodysplastic Syndrome Treatment
Bazinet, A., & Bravo, G. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00965-1 · Cited by 40
Ptashkin, R. N., Ewalt, M. D., Jayakumaran, G., Kiecka, I. J., Bowman, A. S., Yao, J., Casanova, J., Lin, Y.-T. D., Petrova‐Drus, K., Mohanty, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42585-9 · Cited by 39
Self-citationTP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 39
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Loscocco, G. G., Rotunno, G., Mannelli, F., Coltro, G., Gesullo, F., Pancani, F., Signori, L., Maccari, C., Esposito, M., Paoli, C., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27136 · Cited by 37
Bewersdorf, J. P., Shallis, R. M., Gowda, L., Wei, W., Hager, K. M., Isufi, I., Kim, T. K., Pillai, M. M., Seropian, S., Podoltsev, N. A., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1759051 · Cited by 37
Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
Porpaczy, E. A., Wohlfarth, P., Königsbrügge, O., Rabitsch, W., Skrabs, C., Staber, P. B., Worel, N., Müllauer, L., Simonitsch‐Klupp, I., Kornauth, C., et al. (2021) · Cancers · doi:10.3390/cancers13225592 · Cited by 36
Sollier, E., Kuipers, J., Takahashi, K., Beerenwinkel, N., & Jahn, K. (2023) · Nature Communications · doi:10.1038/s41467-023-40378-8 · Cited by 36
AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy
Yan, B., Claxton, D. F., Huang, S., & Qiu, Y. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.06.003 · Cited by 37
Fang, H., Wang, S. A., Khoury, J. D., Hussein, S. E., Kim, D. H., Tashakori, M., Tang, Z., Li, S., Hú, Z., Jelloul, F. Z., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280487 · Cited by 36
Lontos, K., Saliba, R. M., Kanagal-Shamanna, R., Özcan, G., Ramdial, J., Chen, G., Kadia, T., Short, N. J., Daver, N. G., Kantarjian, H., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014499 · Cited by 35
Singhal, D., Kutyna, M., Hahn, C. N., Shah, M. V., & Hiwase, D. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0103 · Cited by 39
Bewersdorf, J. P., & Zeidan, A. M. (2021) · Cancers · doi:10.3390/cancers13071610 · Cited by 36
Nguyen‐Khac, F., Bidet, A., Daudignon, A., Lafage‐Pochitaloff, M., Ameye, G., Bilhou‐Nabera, C., Chapiro, É., Collonge‐Rame, M., Cuccuini, W., Douet‐Guilbert, N., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01561-w · Cited by 35
Aguirre, L. E. E., Ali, N. E. A., Sallman, D. A., Ball, S., Jain, A. G., Chan, O., Tinsley, S., Kuykendall, A. T., Sweet, K. L., Lancet, J. E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01910-3 · Cited by 35
Wang, J., Zhuo, Z., Wang, Y., Yang, S., Chen, J., Wang, Y., Geng, S., Li, M., Du, X., Lai, P., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.800267 · Cited by 34
Li, B., An, W., Wang, H., Baslan, T., Mowla, S., Krishnan, A., Xiao, W., Koche, R. P., Liu, Y., Cai, S. F., et al. (2022) · Blood · doi:10.1182/blood.2021014465 · Cited by 38
Stahl, M. F., Bewersdorf, J. P., Xie, Z., Porta, M. G. D., Komrokji, R. S., Xu, M. L., Abdel-Wahab, O. I., Taylor, J., Steensma, D. P., Starczynowski, D. T., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101128 · Cited by 35
Self-citationBadar, T., Nanaa, A., Atallah, E., Shallis, R. M., Guilherme, S. D. C. C., Goldberg, A. D., Saliba, A. N., Patel, A., Bewersdorf, J. P., DuVall, A. S., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01000-2 · Cited by 33
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Zavras, P. D., Sinanidis, I., Tsakiroglou, P., & Karantanos, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055018 · Cited by 33
Genomic landscape of TP53-mutated myeloid malignancies
Abel, H., Oetjen, K. A., Miller, C. A., Ramakrishnan, S. M., Day, R. B., Helton, N., Fronick, C. C., Fulton, R. S., Heath, S. E., Tarnawsky, S. P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010156 · Cited by 35
From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy
Karagianni, P., Giannouli, S., & Voulgarelis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126321 · Cited by 35
The role of next-generation sequencing in hematologic malignancies
Cho, Y. (2024) · Blood Research · doi:10.1007/s44313-024-00010-0 · Cited by 31
TP53-mutated acute myeloid leukemia: how can we improve outcomes?
Sallman, D. A., & Stahl, M. F. (2024) · Blood · doi:10.1182/blood.2024024245 · Cited by 32
Metadata
- Authors
- Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., Levine, M. F., Arango, J. E., Zhou, Y., Solé, F., Cargo, C. A., Haase, D., Creignou, M., Germing, U., Zhang, Y., Gundem, G., Sarian, A., van de Loosdrecht, A. A., Jädersten, M., Tobiasson, M., Kosmider, O., Follo, M. Y., Thol, F., Pinheiro, R. F., Santini, V., Kotsianidis, I., Boultwood, J., Santos, F. P. S., Schanz, J., Kasahara, S., Ishikawa, T., Tsurumi, H., Takaori-Kondo, A., Kiguchi, T., Polprasert, C., Bennett, J. M., Klimek, V. M., Savona, M. R., Belickova, M., Ganster, C., Palomo, L., Sanz, G., Ades, L., Della Porta, M. G., Elias, H. K., Smith, A. G., Werner, Y., Patel, M., Viale, A., Vanness, K., Neuberg, D. S., Stevenson, K. E., Menghrajani, K., Bolton, K. L., Fenaux, P., Pellagatti, A., Platzbecker, U., Heuser, M., Valent, P., Chiba, S., Miyazaki, Y., Finelli, C., Voso, M. T., Shih, L.-Y., Fontenay, M., Jansen, J. H., Cervera, J., Atsuta, Y., Gattermann, N., Ebert, B. L., Bejar, R., Greenberg, P. L., Cazzola, M., Hellström-Lindberg, E., Ogawa, S., & Papaemmanuil, E.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Kyoto University (JP)
- Massachusetts General Hospital (US)
- University of Pavia (IT)
- Josep Carreras Leukaemia Research Institute (ES)
- St James's University Hospital (GB)
- Universitätsmedizin Göttingen (DE)
- Karolinska University Hospital (SE)
- Heinrich Heine University Düsseldorf (DE)
- Université Paris Cité (FR)
- University of Bologna (IT)
- Medizinische Hochschule Hannover (DE)
- Universidade Federal do Ceará (BR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Oxford (GB)
- Gifu Municipal Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Gifu University (JP)
- Chugoku Central Hospital (JP)
- Chulalongkorn University (TH)
- University of Rochester Medicine (US)
- Vanderbilt University (US)
- Instituto de Salud Carlos III (ES)
- University of York (GB)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Leipzig University (DE)
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Tsukuba (JP)
- Nagasaki University (JP)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- University of Rome Tor Vergata (IT)
- Chang Gung University (TW)
- Radboud University Medical Center (NL)
- Hospital Universitari i Politècnic La Fe (ES)
- The Japanese Data Center for Hematopoietic Cell Transplantation (JP)
- Howard Hughes Medical Institute (US)
- Moores Cancer Center (US)
- Stanford Cancer Institute (US)
- Corresponding author
- Papaemmanuil, Elli
- ORCID
- Bernard, Elsa
- Nannya, Yasuhito
- Hasserjian, Robert P.
- Devlin, Sean M.
- Tuechler, Heinz
- Medina-Martinez, Juan S.
- Yoshizato, Tetsuichi
- Saiki, Ryunosuke
- Malcovati, Luca
- Levine, Max F.
- Solé, Francesc
- Cargo, Catherine A.
- Creignou, Maria
- Germing, Ulrich
- Zhang, Yanming
- Gundem, Gunes
- Jädersten, Martin
- Tobiasson, Magnus
- Kosmider, Olivier
- Follo, Matilde Y.
- Thol, Felicitas
- Pinheiro, Ronald F.
- Santini, Valeria
- Boultwood, Jacqueline
- Schanz, Julie
- Kasahara, Senji
- Ishikawa, Takayuki
- Tsurumi, Hisashi
- Takaori-Kondo, Akifumi
- Kiguchi, Toru
- Polprasert, Chantana
- Bennett, John M.
- Savona, Michael R.
- Belickova, Monika
- Ganster, Christina
- Palomo, Laura
- Sanz, Guillermo
- Elias, Harold K.
- Smith, Alexandra G.
- Werner, Yesenia
- Neuberg, Donna S.
- Stevenson, Kristen E.
- Menghrajani, Kamal
- Bolton, Kelly L.
- Fenaux, Pierre
- Pellagatti, Andrea
- Platzbecker, Uwe
- Heuser, Michael
- Valent, Peter
- Miyazaki, Yasushi
- Finelli, Carlo
- Voso, Maria Teresa
- Shih, Lee-Yung
- Fontenay, Michaela
- Jansen, Joop H.
- Cervera, José
- Atsuta, Yoshiko
- Ebert, Benjamin L.
- Bejar, Rafael
- Greenberg, Peter L.
- Cazzola, Mario
- Ogawa, Seishi
- Papaemmanuil, Elli
- Venue
- Nature Medicine
- Published
- 2020-08-03
- Volume
- 26
- Issue
- 10
- Pages
- 1549-1556
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8381722
- OpenAlex
- W3046671820
- Cited by
- 648
- References
- 58
- Citations by year
- 2026: 73 · 2025: 91 · 2024: 106 · 2023: 136 · 2022: 130 · 2021: 87 · 2020: 22
- FWCI
- 59.16
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- doi.org
- Licence
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Amgen
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Celgene (21267)
- Helsinn
- European Hematology Association
- Japan Agency for Medical Research and Development (JP18ck0106353, 19ck0106250h0003, JP19cm0106501)
- Taiho Pharmaceutical
- TG Therapeutics
- Astex Pharmaceuticals
- Sunesis
- Incyte
- Nippon Shinyaku
- Celltrion
- Geoffrey Beene Foundation
- Cancer Research UK (29685)
- Agence Nationale de la Recherche (ANR-18-IBHU-0003)
- Ministry of Education, Culture, Sports, Science and Technology (hp160219)
- Austrian Science Fund (#F4704-B20)
- Ministero dell’Istruzione, dell’Università e della Ricerca (21267)
- Astellas Pharma
- Associazione Italiana per la Ricerca sul Cancro (21267, 5×1000, 20125, 13042, project #21267, IG #20125)
- Genesis Pharma
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Blood Cancer UK (13042)
- Chugai Pharmaceutical
- Pharmacyclics
- Sanofi K.K.
- Japan Society for the Promotion of Science (19H03684, 13042, 18H02836, 26221308, hp160219, 19H05656, 15H05909)
- National Cancer Institute (P30CA008748, K12CA184746, P50CA254838)
- Daiichi Sankyo Europe
- Cilag
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- TP53 mutation, myelodysplastic syndrome, allelic state, monoallelic variants, biallelic variants, genome stability, leukemic transformation, acute myeloid leukemia, complex karyotype, prognosis, treatment response, wild-type p53
- MeSH terms
- Alleles, DNA Mutational Analysis, Female, Gene Frequency, Humans, Male, Mutation, Myelodysplastic Syndromes, Phenotype, Prognosis, Cohort Studies, Survival Analysis, Tumor Suppressor Protein p53, Treatment Outcome, Loss of Heterozygosity, Genomic Instability, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
